01591nam 2200385 450 991058334150332120230120003550.00-12-809445-10-12-809400-1(CKB)4330000000079374(MiAaPQ)EBC4856918(EXLCZ)99433000000007937420170530h20172017 uy 0engurcnu||||||||rdacontentrdamediardacarrierAdverse events and oncotargeted kinase inhibitors /Giuseppe TridenteLondon, England :Academic Press,2017.©20171 online resource (717 pages) illustrations, tablesIncludes bibliographical references at the end of each chapters and index.Introduction -- Kinases -- Kinase inhibitors -- Adverse events -- Imantinib -- Gefitinib -- Erlotinib -- Sorafenib -- Sunitinib -- Dasatinib -- Lapatinib -- Nilotinib -- Pazopanib -- Vandetanib -- Vemurafenib -- Crizotinib -- Ruxolitinib -- Axitinib -- Bosutinib -- Regorafenib -- Cabozantinib -- Ponatinib -- Dabrafenib -- Trametinib -- Afatinib -- Idelaisib -- Ibrutinib -- Overview -- Conclusion and perspectives.Protein-tyrosine kinaseInhibitorsProtein-tyrosine kinaseInhibitors.612.01516Tridente G.101335MiAaPQMiAaPQMiAaPQBOOK9910583341503321Adverse events and oncotargeted kinase inhibitors1916110UNINA